Cannara Biotech (CNSX:LOVE – Get Free Report) has been assigned a $3.25 price target by equities research analysts at TD Securities in a report released on Tuesday,BayStreet.CA reports. The firm currently has a “buy” rating on the stock.
Cannara Biotech Stock Performance
Cannara Biotech Company Profile
Cannara Biotech Inc is a vertically integrated cannabis company building the largest indoor cannabis cultivation facility in Quebec, a modern and secure 625,000 square foot facility. Leveraging Quebec’s low electricity costs, Cannara will produce high-grade indoor cannabis, specializing in derivative products and brands.
Recommended Stories
- Five stocks we like better than Cannara Biotech
- VWAV: Riding the Defense Surge
- Silver $500? The “Deficit Math” says it’s possible.
- Unlocked: Elon Musk’s Next Big IPO
- This makes me furious
- The Foundation Behind Today’s Biggest Tech Trends
Receive News & Ratings for Cannara Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cannara Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
